Table 5.
Adenosine | Exercise | |||||
---|---|---|---|---|---|---|
Variable | Vasoconstrictor | Time | Pre l-NAME | Post l-NAME | Pre l-NAME | Post l-NAME |
FBF (ml min−1) | Phenylephrine | Baseline | 28 ± 2 | 20 ± 4* | 31 ± 5 | 18 ± 7 |
(n = 4) | Pre-phenylephrine | 143 ± 46 | 88 ± 24 | 185 ± 16 | 164 ± 15† | |
Post-phenylephrine | 96 ± 35 | 57 ± 19 | 163 ± 8 | 151 ± 22† | ||
Clonidine | Baseline | 36 ± 7 | 26 ± 4 | 38 ± 7 | 23 ± 3 * | |
(n = 5) | Pre-clonidine | 148 ± 31 | 92 ± 29* | 205 ± 21 | 188 ± 19† | |
Post-clonidine | 78 ± 15 | 45 ± 12* | 185 ± 25† | 171 ± 25† | ||
FVC (ml min−1 (100 mm Hg)−1) | Phenylephrine | Baseline | 31 ± 2 | 21 ± 4* | 35 ± 5 | 18 ± 7* |
Pre-phenylephrine | 166 ± 52 | 94 ± 28 | 194 ± 14 | 163 ± 17* | ||
Post-phenylephrine | 107 ± 37 | 59 ± 20 | 167 ± 15 | 146 ± 22† | ||
Clonidine | Baseline | 42 ± 8 | 27 ± 5* | 44 ± 9 | 24 ± 4 * | |
Pre-clonidine | 172 ± 35 | 101 ± 33* | 226 ± 27 | 188 ± 21* | ||
Post-clonidine | 89 ± 17 | 47 ± 12* | 198 ± 32† | 168 ± 27*† | ||
MAP (mmHg) | Phenylephrine | Baseline | 90 ± 2 | 95 ± 2 | 90 ± 1 | 99 ± 3* |
Pre-phenylephrine | 86 ± 1 | 95 ± 2 | 95 ± 3 | 101 ± 2 | ||
Post-phenylephrine | 89 ± 2 | 96 ± 2* | 97 ± 4 | 104 ± 1† | ||
Clonidine | Baseline | 89 ± 2 | 94 ± 1 | 88 ± 1 | 99 ± 2* | |
Pre-clonidine | 86 ± 2 | 92 ± 1 | 91 ± 3 | 100 ± 3 *† | ||
Post-clonidine | 89 ± 3 | 96 ± 1* | 96 ± 4 | 103 ± 2† |
P < 0.05 post vs. pre l-NAME within same hyperaemic condition
P < 0.05 exercise vs. adenosine within same l-NAME condition.